Related Experiment Video
Updated: Jul 8, 2026

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
[Neuropathology of mild cognitive impairment Alzheimer's disease]
1Department of Neuropathology, Tokyo Metropolitan Institute of Geriatrics.
Abstract:
The pathological study of mild cognitive impairment (MCI) was very few. Consecutive 1,628 autopsy cases from the Brain Bank for Aging Research (BBAR) with the mean age of 80.7 years were employed for this study. All the cases were studied with the BBAR protocol (www.mci.gr.jp/BrainBank/) and clasasified into Braak's seven neuforibrillary tangle (NFT) stages (0-VII) and four senile plaque (SP) stages (0-C). CDR from the most recent 545 cases were independently evaluated by three neurologists in two different occasions. Among the 1,628 cases, 10.1% fulfilled morphological requirement of Alzheimer disease, consisting of NFT stage equal to or more than IV and SP stage equal to or more than C. Postmortem assessment of CDR was possible for 486 cases amoug 545 cases with frozem half brain and 57 cases were classified into CDR 0.5. CDR 0.5 group was clinicopathologically classified into 33 cases with degenerative changes, nine cases with vascular changes and four cases with combined degenerative and vascular changes. Only 6 among the 57 cases presented pure AD pathology. These data indicate that the pathological background of MCI is not always Alzheimer disease and combined pathology with AD as well as non-AD pathology should be carefully ruled out. For this purpose, ADNI (Alzheimer Disease Neuroimage Initiative) approach could be useful to identify MCI stage of AD.
Related Concept Videos
Alzheimer Disease ll: Pathophysiology
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction
Dementia l: Introduction
Alzheimer's Disease: Treatment
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

